about gene expression that can be co-registered with highresolution (spatial resolution of 50-100 µm for in vivo rodent imaging) anatomical and functional information. Moreover, these genes enable the longitudinal study of the same subject with unlimited tissue penetration, and they have the potential for clinical translation. The CEST method is a novel approach for generating MRI contrast, in which the dynamic exchange process between an exchangeable proton and the surrounding water protons is used to amplify the desired contrast [28] [29] [30] . CEST MRI is being used for a wide range of applications, and it is particularly suitable for imaging enzyme activity [31] [32] [33] , as well as gene expression 27, 34, 35 .
Here we focus on the enzyme HSV1-TK (that is encoded by the HSV1-tk gene), which phosphorylates a wide range of nucleosides and their synthetic analogs. Before phosphorylation, these analogs facilitate transport mechanisms to cross the cell membrane. Once it has been phosphorylated by the HSV1-tk, the transported nucleoside becomes negatively charged and accumulates inside the cell 14 . The accumulation of high levels of the nucleosides in cells expressing HSV1-tk, and not in the surrounding tissue, makes the HSV1-tk a successful reporter gene for PET and SPECT applications [12] [13] [14] [15] [16] [17] [18] [19] [20] 36 , using a range of radiolabeled nucleotide analogs. In contrast, mammalian thymidine kinases do not phosphorylate these nucleoside analogs, making these substrates unique reporter probes for imaging HSV1-tk expression.
Here we describe in detail the synthesis of the CEST-MR imaging probe 5-MDHT (Fig. 1) , the steps needed for expressing HSV1-tk in cells, methods for image acquisition and CEST data analysis.
The CEST-MRI reporter probe 5-MDHT is synthesized in four steps (Fig. 1) . 5,6-Dihydrothymidine (compound 1, Fig. 1 ) is obtained via catalytic hydrogenation of thymidine without Synthesis of a probe for monitoring HSV1-tk reporter gene expression using chemical exchange saturation transfer MRI further purification. Purification is carried out after the next step in which the hydroxyls (OH) of the 2′-deoxyribose moiety of the saturated thymidine are protected by silyl-based protecting groups (compound 2, Fig. 1 ). This is followed by methylation of the C-5 position of the dihydropyrimidine ring (compound 3, Fig. 1) . Finally, the protecting groups are removed by reaction with fluoride ion, and the resulting 5-MDHT is purified using silica gel chromatography. For imaging rodents, tens of milligrams of the imaging probe will be sufficient for completing the study, which are quantities that can be reliably obtained with the synthetic steps described in this protocol. Note that for imaging HSV1-tk gene expression in larger subjects, larger quantities of 5-MDHT will be required. For such quantities, one should consider extra caution for the hydrogenation step, in which larger flasks will contain higher volumes of pressured H 2 gas. One should also exercise caution when carrying out the alkylation step, which uses pyrophoric alkyl lithium reagents.
Although the current protocol describes the synthesis of a dihydropyrimidine variant (5-MDHT) as an imaging probe for monitoring gene expression, diyhydrothymidine derivatives may be considered as CEST-MRI contrast agents for other molecular and cellular imaging applications 35 . Dihydropyrimidine derivatives may also be of interest for other scientific fields, as they have an important role in nucleic acid metabolism, DNA and RNA damage processes, as well as in the biosynthesis of t-RNA 37, 38 .
Although the current protocol describes the use of an MRI reporter probe for imaging the HSV1-tk reporter gene expression in a brain tumor model (9L rat glioma; Box 1) transplanted into a mouse brain, a variety of tumor cell lines and a diverse range of cell transplantation sites can be used with these same protocol steps. This protocol describes the basic CEST-MRI data acquisition and the CEST data processing steps (as schematically shown in Figure 2 , with commonly used CEST definitions in Box 2) that are widely used in preclinical and clinical studies, but it also elaborates further on modifications and improvements from previously published imaging protocols 34 .
The described MRI-based reporter system has several advantages, primarily the use of the new imaging probe, 5-MDHT, which has a long shelf life and is stable for a long time period in solution or powder form. This property makes it attractive for longitudinal studies, as well as for nanocarrier loading or sustained drug release systems that require multiple steps and which cannot be accomplished with a radioactive probe. Although the CEST MRI-based methodology has these advantages 35 with respect to imaging the HSV1-tk transgene, it is important to mention that CEST-MRI cannot achieve the high sensitivity of 
Box 1 | Cell and animal preparations
In this protocol, we describe how to use the MRI reporter probe to image HSV1-tk reporter gene expression in a brain tumor model (9L rat glioma) transplanted into a mouse brain. In this box we describe how the cells for this model are prepared and how they are injected into the mouse brain. A similar procedure could be used for different tumor models.
transgenic cell preparation:
For our work, we transfect and select a single HSV1-tk-expressing clone, as previously described in detail 34 . Transfect the 9L rat glioma cells with pcDNA3.1-HSV1-tk plasmid and with Lipofectamine 2000 as the transfection reagent. Select a single expressing clone using 0.5 mg ml −1 G418 antibiotics. By using this approach, the preparation of a stable cell line starting from a single expressing clone, using 0.5 mg ml −1 G418 antibiotics, takes 2-4 weeks. Generation of a stable cell line from a pool of clones takes 1-2 weeks.
This protocol can be applied to a larger array of tumor cell lines and by using other transduction methods (i.e., different expressing vectors, lentiviruses, adenoviruses, etc.), as previously suggested 8, 12, [14] [15] [16] .
transgenic cell transplantation:
For the brain tumor model that we use in our laboratory, stabilize the head of an adult NOD-SCID male mouse in a stereotaxic frame by using ear bars, and inoculate 2 × 10 5 HSV1-tk-expressing 9L cells (9L HSV1−tk ) and wild-type 9L cells (9L wt ) in 2 µl of saline bilaterally into the mouse striatum (coordinates: 0.0 mm posterior to bregma, 2.0 mm lateral to the midline, 3.0 mm ventral to the surface of the skull) to generate intracranial 9L tumors in both hemispheres.
This process takes 1 h per animal. This protocol could be applied to cells that are xenografted into many different locations in the rodent body; however, the number of cells, the injected volume and time of tumor growth should be adjusted for each cell line and location used. nuclear imaging-based strategies for monitoring gene expression. An interesting solution to this problem is to monitor HSV1-tk expression with MRI in combination with PET, which is particularly attractive given the recent availability of combined MR/ PET scanners 39 . This innovative approach will provide the high sensitivity of PET for imaging HSV1-tk, combined with the repetitive acquisition of high-resolution HSV1-tk MR images, which can be overlaid on high-resolution anatomical MR images.
Experimental design CEST MRI.
Owing to the fact that CEST MRI contrast depends on the applied experimental parameters (especially on saturation pulse, B 1 , power and length, see Box 2), it may be beneficial to consider optimizing the CEST parameters if other experimental models (different animal models, tumor cell lines, tumor injection sites and so on) are being used. In addition, it is important to note that the CEST contrast is also dependent on the magnetic field strength, B 0 (the use of an 11.7 T MRI scanner is described in the current protocol), and experimental parameters may need to be optimized for MRI scanners operating at a different magnetic field strength.
Animal models. It is highly recommended that control cells (either nonexpressing HSV1-tk cells or cells that are expressing different control genes) be transplanted into the same animal (contralaterally to the HSV1-tk-expressing cells) and used as internal negative controls. This may help distinguish nonspecific CEST contrast. Alternatively, CEST contrast from the tumor region of interest (ROI) may be normalized to a well-defined ROI on nontumoral normal tissue, thus allowing the use of two different animal groups (expressing versus non-expressing HSV1-tk). By using the described protocol, one should have six subjects in each group to obtain statistically meaningful results; however, if a different experimental model is being used (different cell line, transgene transfection method, injection tumor site, etc.), a different experimental group size may be needed. 
Box 2 | Common definitions and parameters used in CEST-MRI
• S 0 , MRI signal in the absence of a saturation pulse.
• ∆ω, chemical shift offset with respect to that of water protons (∆ω water = 0 p.p.m.).
• S, MRI signal in the presence of a saturation pulse applied at a particular offset (∆ω i.e., S ∆ω ).
• Z-spectrum, plot of the normalized water signal (S/S 0 ) as a function of saturation frequency ∆ω.
• MTR asym , magnetization transfer ratio asymmetry, defined as 100 × (S −∆ω − S ∆ω ) / S 0 . It is the most common parameter used in CEST-MRI owing to its ability to remove the effect of direct water saturation, which is symmetric around the water resonance frequency (0.0 p.p.m.), thus improving CEST quantification.
• B 0 , magnetic field strength of the MRI scanner used for the study.
• B 1 , field strength of the applied radiofrequency saturation pulse (in Hz or µT units).
• t sat , length (time) of the applied radiofrequency saturation pulse (in milliseconds). Mice (immune-deficient, 6-8-week-old male mice from in-house strains or from an appropriate provider) ! cautIon All involved personnel should be trained in animal handling. The animal protocol must be reviewed and Adjust the pH of the resulting solution to 7.4.  crItIcal 4% (wt/vol) PFA should be freshly prepared before use. However, if storage is required, 50-ml aliquots may be stored at −20 °C for several weeks.  crItIcal Perform all experiments that relate to cell preparation using sterile techniques. 9L cell medium 9L cell medium contains 500 ml of 1640 RPMI, 5 ml of l-glutamine solution, 5 ml of sodium pyruvate solution, 0.6 ml of gentamycin, 5 ml of amphotericin B solution and 1.7 µl of 2-mercaptoethanol. Store it at 4 °C for up to 3 months. DAPI solution Prepare a stock solution of 5 mg DAPI in 1 ml of dH 2 O. Dilute 5 µl of DAPI stock solution in 10 ml of dH 2 O to prepare a DAPI working solution.  crItIcal DAPI working solution should be stored at 4 °C in a 50-ml tube wrapped with aluminum foil to prevent light.
MaterIals

REAGENTS
• • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •
EQUIPMENT SETUP MR scanner
The MR scanner should be set up according to the manufacturer's instructions. A horizontal-bore, 7-, 9.4-or 11.7-Tesla MRI system is preferred for better animal access; however, a vertical MRI scanner can be used as well. The MR spectrometer should be equipped with an animal holder specifically designed for mouse brain imaging. Note that a volume radiofrequency (RF) coil is preferable for CEST-MRI experiments in order to achieve a homogenous B 1 . Mice are initially placed in an induction chamber containing 4% (wt/vol) isoflurane. They are then positioned in the scanner, and kept anesthetized with an isoflurane vaporizer (~1-2% (wt/vol) isoflurane with air or oxygen) attached to a nose cone.  crItIcal An MRI-compatible respiration rate monitoring system should be used to ensure that the mouse's respiration rate is maintained at 30-60 breaths per min by adjusting the dose of anesthesia using the vaporizer.
• 
4|
Evacuate the H 2 gas and repeat filling and evacuating H 2 three times to flush traces of oxygen.
5|
Fill the reaction flask with 50 p.s.i. of H 2 and stir the reaction mixture for 2 h at room temperature.
6|
Cautiously evacuate the H 2 gas, remove the pressure gauge and withdraw 50 µl of the reaction mixture for monitoring the reaction for completion. Place a drop from the reaction mixture on a silica gel-coated TLC plate, dry it and confirm the disappearance of the thymidine spot under UV light, indicating reaction completion. Use a solution of thymidine (20 mg in 3 ml methanol) as positive control. Note that a loss of UV activity is obtained when thymidine is converted to 5,6-dihydrothymidine. There is no need to run the TLC plate in a developing chamber.
7|
If required (uncompleted reaction as determined by TLC, Step 6), equip the reaction flask with the pressure gauge (Step 3) and refill it with 50 p.s.i. of H 2 . Repeat Steps 4-6 until the reaction is complete.
8| Add Celite to a sintered glass filter (an ~2-cm-thick layer) and wash it three times with 30 ml of methanol each time.
Increase the rate of methanol passage through the Celite by either forcing the solvent through, using air, or filtering under a vacuum, using an aspirator.
9|
Pour the reaction mixture (Steps 5 and 6, after the reaction is complete) onto the Celite-containing filter (Step 8), and wash it three times with 30 ml of methanol to recover the product and separate it from the catalyst.
10|
Transfer the filtrate to a round-bottom flask and remove the solvent using a rotary evaporator. Heat the evaporating solution in a water bath (50 °C) to allow complete removal of the water from the reaction mixture.
? trouBlesHootInG 11| Proceed to the next step (Step 12) using the crude product without further purification.  pause poInt Flush the round-bottom flask containing the crude product (Step 10) with argon (or nitrogen) gas, seal it with Parafilm and store it at 4 °C for future experiments. 13| Add 4 ml of dry pyridine and equip the flask with a vacuum/inert gas adaptor and place the flask in a water bath at room temperature.
14|
Connect the flask to a Schlenk line, stir the reaction mixture to dissolve 5,6-dihydrothymidine (1) and purge it with argon (or nitrogen) gas.
15| Open the system to high vacuum until all the solvent is removed (~3-5 h).
16| Vent the flask to argon (or nitrogen) gas. ! cautIon Place the vacuum system in a fume hood and wear safety glasses for protection when you are working with a high-vacuum system.
production of 5-MDHt, part 3: synthesis of 3′,5′-O-bis(tert-butyldimethylsilyloxy)5,6-dihydrothymidine (2)
• tIMInG variable; purification takes 2-3 h 17| Add 10 ml of dry pyridine to 0. 
19|
Flush the reaction mixture with argon (or nitrogen) gas and stir the reaction mixture under an argon (or nitrogen) gas atmosphere.
20|
Monitor the reaction progress by TLC after a 'mini work-up' step, as follows: transfer 50 µl of the reaction mixture, via a dry syringe, to a 1.5-ml plastic tube and add 0.5 ml of saturated NaHCO 3 solution and 0.5 ml of ethyl acetate. Mix the contents well to extract, let the tube sit for phase separation, and then spot, on a TLC plate, one drop from the top organic layer. Develop the plate in a developing jar with a mixture of EtOAc/hexanes (4:1 volume ratio). Monitor the reaction progress by staining the TLC plate with PAA solution after heating the plate. The R f values are 0.75 for the product and 0.25 for the mono-TBDMS compound.
21| After verification of reaction completion using TLC (
Step 20), add 20 ml of saturated NaHCO 3 solution and 20 ml of water to terminate the reaction. Pour the resulting mixture into a 150-ml separating funnel.
22| Extract three times with 20 ml of diethyl ether and combine the organic phase layers (top layer).
23| Wash the combined organic phase with 50 ml of brine, dry the organic phase using MgSO 4 , filter it through a filter paper and remove the solvent using a rotary evaporator. No heating of the evaporating solution is required.
24|
Load the crude product onto a silica gel column (1:50 weight ratio of crude: silica gel) and separate the main product from the reagents and by-product(s) by using a mixture of EtOAc/hexanes (4:1 volume ratio) as the eluent.
25|
Collect fractions (~10 ml) until the compound is completely eluted (determine by TLC, see Step 20) , combine the fractions containing the product and evaporate the solvent by using a rotary evaporator. To validate the synthesis of pure 3′,5′-O-bis(tert-butyldimethylsilyloxy)-5,6-dihydrothymidine (2), dry the product under high vacuum, perform 1 H-NMR and compare the spectrum with previously published 1 H-NMR data 40, 41 .
? trouBlesHootInG  pause poInt Flush the product with argon (or nitrogen) gas, seal it with Parafilm and store it at 4 °C for future experiments.
production of 5-MDHt, part 4: synthesis of 3′,5′-O-bis(tert-butyldimethylsilyloxy)-5-methyl-5,6-dihydrothymidine (3)
• tIMInG 6-7 h 26| Distill 1 ml of iodomethane (CH 3 I), boiling point 41-43 °C, under an argon (or nitrogen) gas atmosphere. Collect the dry distilled iodomethane and seal it with Parafilm for use in the next step. ? trouBlesHootInG 27| Weigh 0.7 g (1.5 mmoles, 1 equivalent) of 3′,5′-O-bis(tert-butyldimethylsilyloxy)-5,6-dihydrothymidine (2) into a 50-ml round-bottom flask equipped with a magnetic stir bar, dissolve it in 2 ml of pyridine and azeotropically dry it as described in Steps 12-16.
28|
After removing all pyridine, equip the reaction flask with a septum and add 15 ml of THF, dissolve compound 2 and cool the reaction flask to −78 °C by using dry ice/acetone.
29|
Use a dry syringe to carefully add 2.7 ml of sec-butyllithium (sec-BuLi) solution (1.4 M in cyclohexane, 3.75 mmoles, 2.5 equivalents) over a 5-min period. Stir the flask for 1 h at −78 °C.
30|
Add 0.14 ml of distilled iodomethane (Step 25, 2.25 mmoles, 1.5 equivalents) to the stirred reaction mixture ( Step 29) and leave it at −78 °C for 1 additional hour.
31|
Warm the reaction to room temperature and quench it with 200 ml of saturated NH 4 Cl solution.
32| Extract the resulting mixture three times with 250 ml of EtOAc. Combine the organic phases and wash the mixture with 500 ml of brine, dry it over Na 2 SO 4 , filter it through a filter paper and remove the organic solvent with a rotary evaporator.
33| Dilute 10 µl of crude product (in 100 µl hexanes), spot the solution using a capillary tube on the TLC plate and run it in a developing chamber by using an EtOAc/hexanes mixture (1:4 volume ratio). Check the plate using PAA solution.
The R f values are 0.3 for the dimethyl product (3) 
38|
Monitor the reaction progress and completion by TLC, by using a dichloromethane/methanol mixture (92:8 volume ratio). Check the plate using PAA solution. The R f value of the product is 0.25. ? trouBlesHootInG 39| After the reaction is complete, remove the solvent with a rotary evaporator (no heating of the evaporating solution is required), load the crude product onto a silica gel column (1:50 weight ratio of crude:silica gel) and separate the main product from reagents and by-products by using a dichloromethane/methanol mixture (92:8 volume ratio) as the eluent. ? trouBlesHootInG 40| Collect the fractions (~10 ml) until the compound is completely eluted (determine by using TLC; see Step 38) 43| Two hours after probe injection, anesthetize the mouse with 2-3% (wt/vol) isoflurane air gas; restrain the mouse in a holder, centering at both the center of the RF coil and the center of the magnet. Keep the mouse anesthetized throughout the imaging procedure using 1.5% (wt/vol) isoflurane gas inhalation. ! cautIon At least one of the physiological parameters, such as respiration or body temperature, must be closely monitored, and the percentage of isoflurane should be adjusted accordingly to maintain a proper state of anesthesia.
44|
Determine the appropriate slice to image by using a localizer sequence, such as tripilot RARE, available for the Bruker MRI scanners.
45|
Adjust the B 0 shimming to a satisfactory level by using either an automatic shimming protocol, such as FieldMAP (Bruker), or by performing manual shimming. ! cautIon Do not forget to readjust the resonance frequency offset back to 0 after adjusting shimming. 
49|
The data-processing procedure should match the chosen data-acquisition procedure (Step 48A or 48B). 
53|
Cryopreserve the brains by submerging them in 50 ml of a 30% (wt/vol) sucrose solution (in PBS) for 24-48 h, and then freeze the tissue on dry ice.  pause poInt Frozen brains can be stored for 1 year at −80 °C.
54|
Quickly transfer the frozen brain into a precooled cryostat chamber (−21 °C). Allow the tissue temperature to equilibrate and mount the tissue on a specimen holder.
55| Cut 30-µm-thick slices and mount the slices from the regions of interest (tumor) on microscope slides.
56|
Block the slices on slides for 1 h at room temperature with PBS containing 5% (wt/vol) BSA; follow this by overnight incubation (4 °C) in anti-V5 antibody solution (1:500 dilution in an antibody diluent reagent solution).
57|
Wash the slides three times for 5 min with PBS, and incubate them for 1 h with an appropriate secondary fluorescent antibody (for example, Alexa Fluor 594 goat anti-mouse IgG (H+L), 1:400 dilution, in a blocking solution). Wash the slides three times for 5 min with PBS and stain them for nuclei with 1 µg ml −1 DAPI solution for 10 min.
58|
Wash the DAPI solution with PBS, apply mounting medium and cover the slides with a coverslip.  pause poInt Slides may be stored for 2-3 months at 4 °C in the dark for further analysis.
59| Confirm the expression of the HSV1-tk fused to V5 by evaluating the immunofluorescence staining of the tumor of interest (Fig. 3) .
? trouBlesHootInG Troubleshooting advice can be found in table 1. • tIMInG Steps 1-11, production of 5-MDHT, part 1: synthesis of 5,6-dihydrothymidine (1): the reaction should be completed in 2 h, as determined by TLC Steps 12-16, production of 5-MDHT, part 2: azeotropic drying of 5,6-dihydrothymidine (1): azeotropic drying should take 3-5 h (depending on the solvent volume and the vacuum pressure in the system) Poor separation between reagent and product using silica gel column Use a higher weight ratio of crude product to silica gel (>1:100) Perform a second separation procedure to increase purity The conversion of thymidine to compound 1 (Steps 1-10) should be completed within 2 h; however, the reaction mixture may be stirred overnight if desired, for up to 18 h (as determined by TLC, Step 6). In case of poor conversion, refer to TROUBLESHOOTING. The overall yield for compound 2 should be 75%. TLC: EtOAc/hexanes mixture (4:1 volume ratio), R f = 0.75. In case of poor yield, refer to TROUBLESHOOTING. See previously published 1 H-NMR results 40, 41 and compare them with your 1 H-NMR data. 
cest-MrI
CEST-MRI contrast difference between wild-type tumor and HSV1-tk-expressing tumors. A concentration of 0.5-1.0 mM of 5-MDHT should be accumulated to generate significant CEST contrast in HSV1-tk-expressing cells compared with controls at the frequency offset of the imino exchangeable proton of 5-MDHT (Fig. 4) . 
